|Videos|December 25, 2019
HER2+ mBC: DESTINY-Breast04 Trial
Author(s)Sponsored Content
The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.
Advertisement
The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Reflecting on My Sister’s Final Days After Years of Unexpected Rebounds
2
Every FDA Oncology Approval From November 2025
3
Chemo Side Effects for Breast Cancer Led to Weeks in the Hospital
4
KRd Improves Progression in Newly Diagnosed Patients With Myeloma
5
